New hope for second kidney transplants: drug aims to stop body from rejecting future grafts
NCT ID NCT04779957
Summary
This study tested if a single dose of the drug tocilizumab, given around the time a failed kidney transplant is surgically removed, is safe and can help reduce harmful antibodies. These antibodies often form after removal and make it very difficult for patients to receive a second transplant. The main goal was to check for serious infections or other complications, while also seeing if the drug lowered antibody levels one year later.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Toulouse
Toulouse, France
Conditions
Explore the condition pages connected to this study.